AMGN ▲ +0.1% - Amgen Inc.
$AMGN AMGN - FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA®
Amgen rose 0.1% following FDA approval to reduce monitoring time for the first two doses of its cancer immunotherapy Imdelltra, a regulatory change that streamlines the treatment protocol and may improve patient convenience and clinical efficiency.
14-SEP-2026 09:03 AM ET
Share this post
More filings for $AMGN
AMGN ▼ -0.4% - Amgen Inc.Sep 9, 2026AMGN ▼ -5.8% - Amgen Inc.Sep 8, 2026AMGN ▼ -7.1% - Amgen Inc.Sep 4, 2026AMGN ▲ +1.5% - Amgen Inc.Sep 2, 2026AMGN ▼ -0.2% - Amgen Inc.Aug 31, 2026
View full $AMGN filing history →💬 Comments
Loading comments…
Leave a comment
